Background/Objectives: Surgical site infection (SSI) after surgery for inflammatory bowel disease (IBD) has not been described microbiologically in the Arabian Peninsula, where extended-spectrum beta-lactamase (ESBL) prevalence is high and prophylaxis remains largely cephalosporin-based. We described the microbiology of SSI after IBD surgery and the extent to which recovered microorganisms were expected to be covered by the prophylaxis administered. Methods: We retrospectively studied consecutive gastrointestinal operations for IBD at a tertiary center in Jeddah, Saudi Arabia (April 2014 to November 2025). Of 118 eligible operations, 8 performed through a dirty/infected wound were reported separately, leaving a primary cohort of 110 operations in 91 patients. The primary outcome was deep incisional or organ/space SSI by CDC/NHSN criteria; models used cluster-robust standard errors for repeated operations. The microbiological analysis was exploratory. Results: SSI followed 33 of 110 operations (30.0%; 95% CI 22.2–39.1), of which 22 (66.7%) were deep or organ/space. Cultures were positive in 23 of 33 infections; because specimens were obtained at clinician discretion, microbiological estimates apply to this subset only. An acquired resistance phenotype was recorded in 10 of 23 (43.5%): ESBL-producing Enterobacterales in 8 and methicillin-resistant Staphylococcus aureus in 2. All operations received prophylaxis within 60 minutes of incision, but five regimens were in use. Expected non-coverage of at least one isolate, assigned from recorded phenotype and intrinsic resistance, was present in 7 of 11 culture-positive infections after cephalosporin-based prophylaxis (63.6%; 95% CI 35.4–84.8) and 0 of 12 after broader-spectrum regimens, with 5 indeterminate. Low preoperative serum albumin and absence of IBD-directed therapy were associated with deep infection after adjustment; emergent surgery was not, although it was in a sensitivity analysis that included the dirty/infected operations. Conclusions: These findings describe prophylaxis–spectrum discordance and support microbiological surveillance and locally informed review of prophylaxis policy rather than empirical broadening.
No takes yet. Share an insight, caveat, or question.
Farsi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: